Cyxone step up activities and extend collaboration with global CRO around RA trial
Cyxone (publ) announces today that the company has signed a Letter of Agreement (LOA) with the internationally renowned clinical contract research organization (CRO) following on an early operations agreement (EOA) signed last month. The LOA is a key step for advancing the clinical phase 2b trial of Rabeximod in patients with rheumatoid arthritisThe agreement enables Cyxone to expand and intensify start-up activities for the phase 2b trial including site selections and regulatory submissions enabling an efficient route to enrolling patients into the trial within the shortest period of time.